Growth Metrics

Gyre Therapeutics (GYRE) Retained Earnings (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Retained Earnings for 16 consecutive years, with -$68.4 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 2534.81% to -$68.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$68.4 million through Dec 2025, down 2534.81% year-over-year, with the annual reading at -$68.4 million for FY2025, 2534.81% down from the prior year.
  • Retained Earnings for Q4 2025 was -$68.4 million at Gyre Therapeutics, down from -$66.7 million in the prior quarter.
  • The five-year high for Retained Earnings was $7.4 million in Q4 2022, with the low at -$417.2 million in Q1 2022.
  • Average Retained Earnings over 5 years is -$177.0 million, with a median of -$73.9 million recorded in 2024.
  • Peak annual rise in Retained Earnings hit 101.84% in 2022, while the deepest fall reached 18280000.0% in 2022.
  • Over 5 years, Retained Earnings stood at -$402.7 million in 2021, then surged by 101.84% to $7.4 million in 2022, then plummeted by 122.23% to -$1.6 million in 2023, then tumbled by 57.97% to -$2.6 million in 2024, then plummeted by 2534.81% to -$68.4 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$68.4 million, -$66.7 million, and -$2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.